DRUG LEVELS OF LOPINAVIR/RITONAVIR IN MEN AND WOMEN

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。A5223是一项对78名HIV-1感染者进行的非随机前瞻性评估，旨在确定LPV在男性和女性中的药代动力学(PK)。受试者将按性别、种族和民族进行分层。他们将在服用早晨剂量的洛匹那韦/利托那韦(LPV/RTV)之前和12小时后获得的血浆样本上进行药代动力学评估。这项研究将使我们开始更好地了解抗逆转录病毒药物在女性中的安全性和有效性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5223 is a non-randomized prospective evaluation of 78 HIV-1- infected subjects designed to determine the pharmacokinetics (PK) of LPV in men and women. Subjects will be stratified by sex, race and ethnicity. They will undergo pharmacokinetic evaluations on plasma samples obtained prior to and up to 12 hours after the administration of the morning dose of lopinavir/ritonavir (LPV/RTV). This study will allow us to begin to have a better understanding of the safety and efficacy of antiretroviral agents among women.